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meningococcal disease conditional on carriage (q) to US inci-
dence data. Calibration used the maximum likelihood method;
goodness-of-ﬁt was assessed using deviance. RESULTS: The cal-
culated b for infant-to-infant transmission is 1.86 effective con-
tacts per 100,000 infants per year. b peaks at 29.7/100,000 for
transmission between 14 year olds and 11–14 year olds, and
ranges from 0 to 16.3/100,000 for adult-adult transmission. The
q is highest in infants (0.015), declines steeply and plateaus at
0.00013 in those aged >20 years. The model predicted yearly
cases of ACWY-related meningococcal disease are 132 among
infants, 439 among 1–20 year-olds, and 202 among those aged
>20, compared with 129, 433, and 211 for US benchmarks
(deviance = 184, with 72 degrees of freedom). CONCLUSIONS:
Calibration techniques can be used to adapt a UK meningococcal
disease model to the US using modiﬁed serogroup and contact
data such that a reasonable ﬁt is achieved with US benchmarks.
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OBJECTIVES: To determine the relation with active smoking
patients in presence of asthma and COPD, and to know its
association with some cardiovascular risk factors and its cost
repercussion of attended patients in a Spanish population setting.
METHODS: Multi-centric retrospective design realised begin-
ning from subjects older than 14 years demanding assistance
during year 2006. Smoking habit, asthma and COPD were
deﬁned as a clinical illness obtained according to International
Classiﬁcation CIAP-2. Main measures: age, gender, co-
morbidities (cardiovascular), Charlson index (patient severity)
and costs model (ﬁxed/semi-ﬁxed: in operation) and variable
ones (diagnostics/therapeutics tests and referrals). Statistic analy-
sis: logistics regression and covariance (ANCOVA) for the
correction of the model (recommendations: Thompson-Barber).
Program SPSSWIN, p < 0.05. RESULTS: A total of 65,768
patients (use: 73.1%; frequentation: 4.7 visits/100 inhabitants).
The 4.1% (n = 2,693, conﬁdence intervals of the 95% [CI]:
3.9–4.3%) presented asthma and the 2.7% (n = 1,769, CI: 2.6–
2.8%) COPD. The percentage of active smokers was 20.2% (CI:
18.7–21.7%) and 27.0% (CI: 24.9–29.1%), p = NS, respectively.
In general, asthmatic patients were associated to feminine gender
(OR = 1.7) and in younger ages (15–44 years: 52.2%),
p < 0.001; while COPD to masculine gender (women: OR = 0.2),
older ages (65–74 years: 64.5%) and cardiovascular events (OR:
1.2). In both patients of high co-morbidity and with obesity
(OR = 1.5 and OR = 1.4; in asthma and COPD respectively).
The average of adjusted total cost/unitary was superior in COPD
(€1,146.30) especially in pharmaceutical cost. CONCLUSIONS:
The existence of active smoking patients in presence of asthma
and COPD is high. In primary prevention should be established
measures to carry out the reduction of cardiovascular risk factors
(smoking and obesity), above all in subjects with COPD, were
the resources consume and risks are higher.
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OBJECTIVES: To investigate the relative effectiveness of inhaled
cortcosteroids (ICS) and leukotriene-receptor anragonists to
prevent moderat-to-severe exacerbations among asthmatic chil-
dren. METHODS: From the linkage of two administrative health
databases from Quebec, Canada, we reconstructed a cohort of
asthmatic children aged 5 to 15 years that initiated a treatment
with either ICS or LTRA between January ﬁrst 1998 and August
31, 2005. Patients were followed between 4 and 12 months. The
primary outcome was moderate-to-severe asthma exacerbations
deﬁned as an emergency department (ED) visit for asthma, a
hospitalization for asthma or a dispensed short-course (14
days) prescription of oral corticosteroids. Patients’ adherence to
their controller therapy was estimated with the medication pos-
session ratio (MPR). All analyses were stratiﬁed by the presence
or not of an asthma exacerbation in the year before treatment
initiation with ICS or LTRA. We estimated the adjusted rate
ratios of moderate-to-severe asthma exacerbations comparing
patients treated with ICS and LTRA with Poisson regression
models including a dispersion parameter. The mean MPR was
compared between ICS and LTRA users with a t-test. RESULTS:
A total of 27,355 children were included in the cohort: 7,494
(27%) with and 19,861 (73%) without an exacerbation in the
year prior to treatment initiation. Among children with no exac-
erbation before treatment initiation, the risk of exacerbations
was signiﬁcantly more than twice with ICS versus LTRA
(adjusted RR = 2.3; 95% CI; 1.3–4.0), while the RR was not
signiﬁcant among children who had at least 1 exacerbation
before treatment initiation (adjusted RR = 1.6; 95% CI: 0.8–
3.1). The mean MPR was 0.16 for ICS compared to 0.35 for
LTRA, among children with at least 1 exacerbation prior to
treatment initiation (p < 0.001). These means were 0.15 and
0.30, respectively, among children with no previous exacerbation
(p < 0.001). CONCLUSIONS: Among children free of exacerba-
tions prior to treatment initiation, our study showed that ICS
users were more than twice more likely to have an exacerbation
than LTRA users and that higher adherence to LTRA may have
accounted for this result.
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OBJECTIVES: To identify subjects affected by Chronic Obstruc-
tive Pulmonary Disease (COPD) in a local health authority of
approximately 441 thousand inhabitants situated in Campania,
a region in the southwest of Italy. METHODS: A retrospective
naturalistic longitudinal study was conducted using record
linkage between administrative health services databases (drug
prescription, hospital admissions, demographic). We enrolled
subjects with greater than or equal to 45 years old who had
during the period 2006/2007 an hospital admission for Chronic
Bronchitis (ICD-9 cod.491) and/or received drugs chronic pre-
scription for obstructive diseases from the R03 Anatomical
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Therapeutic Chemical Classiﬁcation group. Subjects with a hos-
pital admission for asthma (ICD-9 cod.493) and/or a prescrip-
tion of drugs with indication for an allergenic disease (R03DC,
R03BC) were excluded. RESULTS: A cohort of 12,212 COPD
affected patients (51.5% males) was selected, 11,726 received
drug prescription and 1,405 were hospitalized. Only the 7 % of
the cohort was recognized from both electronic databases. Strik-
ingly, the 39% of subjects selected with a hospital admission for
COPD did not received drugs chronic prescription. The esti-
mated prevalence in adult population (>= 45 years old) was
6,3% and was higher in males (7.1%) than in females (5.7%).
Stratifying by age the prevalence was highest in subjects with
more than 75 years and is twice in males. CONCLUSIONS:
From the administrative database it was possible to provide an
estimation of the prevalence of COPD in a particular area of
Campania. Further research will validate our results, in particu-
lar, in future we will be able to describe therapeutic proﬁles of
patients and we will try to understand why a high percentage of
subjects with an hospital admission for Chronic Bronchitis
receive no medication.
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OBJECTIVES: To assess whether sub-acute lack of asthma
control (SALAC) and its components, high SABA use and out-
patient asthma visits, predict subsequent asthma exacerbations in
a managed care population. METHODS: The HealthCore Inte-
grated Research Database was used to identify asthmatics, aged
6–64, with 3 years continuous enrollment from January 1, 2003–
December 31, 2005. Study inclusion criteria: 32 outpatient visits
or 31 hospitalization/emergency department (ED) visit with
asthma diagnosis (ICD-9-CM 493.xx) in a year. SALAC deﬁni-
tion: >4 outpatient asthma visits or >5 SABA prescriptions per
year. Annual acute asthma exacerbation (AAE) deﬁnition: 31
hospitalization/ED visit with primary asthma diagnosis or oral
corticosteroid burst. Separate generalized estimating equations
(GEEs) modeled risk of subsequent year AAEs, as a function of:
a) age, gender, geographic region, prior year AAEs and SALAC
and b) age, gender, geographic region, prior year AAEs and high
SABA use/outpatient asthma visits, to determine the independent
impact of prior year SALAC and its components on subsequent
year AAEs. RESULTS: Of 35,806 asthmatics, 47% were male
with mean age 31.6  17.9 years. During 2003–2005, 12.1% of
patients exhibited SALAC, 5.7% had high SABA use, 7.1% high
outpatient asthma visits and the SABA use/outpatient asthma
visit overlap averaged 0.7%. GEE results indicate that, control-
ling for all other variables, prior year SALAC is associated with
increased risk of subsequent year AAE (OR 1.60, 95% CI 1.51–
1.69; p < 0.0001). High outpatient asthma visits and SABA use
are each associated with increased risk of subsequent year AAE
(OR 1.34, 95% CI 1.25–1.44, p < 0.0001 and OR 1.85, 95%
CI 1.72–2.00, p < 0.0001, respectively). CONCLUSIONS: This
study demonstrates that SALAC and its components, high SABA
use and outpatient asthma visits, exhibit signiﬁcant effects in
predicting subsequent AAEs. Use of SALAC may help health
plans identify opportunities to simultaneously improve members’
asthma control and reduce health care utilization associated with
asthma exacerbations.
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Several studies have estimated the incidence and prevalence of
atopic conditions separately. Relatively few attempts have been
made to estimate the extent of co-existence of multiple atopic
conditions. OBJECTIVES: To estimate the age-speciﬁc incidence
and lifetime prevalence of eczema, rhinitis and asthma, alone or
in combination. METHODS: Using General Practice Research
Database (GPRD), a birth cohort of patients registered with UK
general practice within a year following birth and treated in the
same practice for the next twenty years was identiﬁed. The
incidence rate of an atopic condition each year following birth
and the lifetime prevalence of each atopic condition alone or in
combination with others was estimated. RESULTS: Among the
3 conditions, eczema had the highest cumulative incidence of
154.4 per 1000 patients (95%CI:153–156) followed by asthma
(126.3;(95%CI:125–128)) and rhinitis (60;(95%CI:59–61)), by
the age of 20 years. One in three patients diagnosed with eczema
and one in six patients diagnosed with asthma had their condi-
tion diagnosed by the age of 2 years. Eczema also had the highest
lifetime prevalence of clinician-diagnosed disease at 21.1%
(95%CI:20.0–21.3) followed by asthma (15.5%;(95%CI:15.3–
15.6%)) and rhinitis (9.4%;(95%CI:9.3–9.5)). The median age
of diagnosis was 8 years for eczema (IQR:2–20) and asthma
(IQR:3–16), and 16 years for rhinitis (IQR:10–25). 36.3%
(95%CI:36.1–36.5) of children were suffering from at least one
atopic condition and 9.8% (95%CI:9.6–9.9%) were diagnosed
with at least two. About 1.5% of patients were diagnosed with
all three conditions. Among these 32%, 30% and 10% had
eczema, asthma and rhinitis as their herald condition respec-
tively; the remaining 28% having their ﬁrst two atopic conditions
diagnosed at the same age. CONCLUSIONS: Eczema and
asthma showed high co-prevalence and high incidence rates in
early childhood. Among patients developing all three conditions,
a signiﬁcant proportion was diagnosed with at least two of them
by the age of ten years. There is likely to be more than one
variation of the ‘allergic march’ in those with co-morbid allergic
disease.
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